Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK

por Evans, Marc, Berry, Sasha, Malkin, Samuel J. P., Hunt, Barnaby, Sharma, Abheet
Publicado 2023

Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy

por Ren, Hongye, Berry, Sasha, Malkin, Samuel Joseph Paul, Hunt, Barnaby, Bain, Stephen
Publicado 2023

Once‐weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long‐term cost‐effectiveness analysis based on SUSTAIN 11

por Evans, Marc, Chubb, Barrie, Malkin, Samuel J. P., Berry, Sasha, Lawson, Jack, Hunt, Barnaby
Publicado 2022

The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK

por Viljoen, Adie, Chubb, Barrie, Malkin, Samuel J. P., Berry, Sasha, Hunt, Barnaby, Bain, Stephen C.
Publicado 2022